Thyrocare Tech. Q4 FY26 Earnings Analysis

- Long-term sustainable growth is expected to be in the mid-teens range (12%–15%) for the franchise business. - The partnerships business is anticipated to grow about 1.5 times faster than the franchise business, contributing to consolidated mid-teens growth. - The company aims to maintain growth above market rates by strategic investments in franchisee network expansion and specialty offerings. - Specialty segments like allergies and genomics are key areas of investment for future growth and market expansion. - International business (e.g., Tanzania) is growing rapidly, doubling annually, though it remains a small part currently. - Growth in partnerships is driven by onboarding new health tech clients and expanding existing accounts, with specific mention of 39% YoY growth. - Management cautions against overly aggressive growth spending to manage risk but is committed to investing in sustaining above-market growth rates.

- Organic growth of 15-16% over the next 2 years is achievable but will come at a cost; margins expected to remain stable, not improve significantly. - Reported EBITDA margins are currently around 32-34%, with further margin improvement unlikely as investments in specialty areas continue. - Consolidated revenue growth is projected in the mid-teens, driven by 12-15% growth in franchise business and 1.5x (around 18-22%) growth in partnership business. - EPS growth was 39% YoY in Q3 FY '26; future EPS growth expected to align with mid-teens revenue growth and stable margins. - Investments in new growth areas like genomics and allergies are planned, which may moderate margin expansion but support longer-term growth. - Capex of INR 20-30 crores excluding ROU capitalization indicates continued reinvestment for expansion.

- The company plans a field expansion with 40 new field personnel expected in the next financial year. - There are ongoing investments in specialty offerings, including setting up specialty labs and expanding the internal sales and doctor network (currently 80 doctors on staff). - Capex so far this financial year is approximately INR 20-30 crores, excluding ROU (Right of Use) asset capitalization. - ROU asset capitalization related to reagent rental machines increased to around INR 22-23 crores this year from INR 13 crores last year. - Strategy on capex remains unchanged: buy equipment where cost-effective and use reagent rental models where advantageous, e.g., biochemistry on reagent rental, immunoassay machines bought. - Investment focus includes genomic testing (new platform finalized) and allergy testing (already live), viewed as growth drivers. - International expansion is cautious; currently only in Tanzania, seen as a nascent market.

- There is no mention of any current or planned new fundraising through debt or equity in the provided transcript. - The management discussion focuses on business growth, partnerships, investments in specialty offerings, and operational strategies. - No statements indicate intentions for raising funds via equity or debt in the near future. - Existing investments, such as capex for equipment and reagent rental models, are internally managed. - The company emphasizes sustaining growth through operational investments rather than external fundraising.

- The transcript does not explicitly mention the current or expected orderbook or pending orders for Thyrocare Technologies Limited. - However, there is discussion about partnership onboarding and growth: - The company has onboarded 5 out of 16 insurance TPAs (Third Party Administrators), up from 3 previously. - The partnership business accounts for around 33% of revenue. - Business growth expectations remain positive with targeted organic growth of 15-16% over the next 2 years. - The company highlights sustained demand and scaling via franchisee and partnerships, with 200 franchisee additions this quarter. - There is no specific quantified data on pending orders or exact orderbook metrics provided in the transcript on page 20 or surrounding pages.